Can We Improve Nonmuscle Invasive Bladder Cancer Guideline Adherence With Smarter Risk Stratification?
- PMID: 29906436
- DOI: 10.1016/j.juro.2018.06.019
Can We Improve Nonmuscle Invasive Bladder Cancer Guideline Adherence With Smarter Risk Stratification?
Comment on
-
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23. Eur Urol. 2016. PMID: 26210894 Clinical Trial.
-
Bladder cancer: Low adherence to guidelines in non-muscle-invasive disease.Nat Rev Urol. 2016 Oct;13(10):570-1. doi: 10.1038/nrurol.2016.165. Epub 2016 Aug 31. Nat Rev Urol. 2016. PMID: 27578042 Review. No abstract available.
-
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.J Urol. 2017 Oct;198(4):824-831. doi: 10.1016/j.juro.2017.04.077. Epub 2017 Apr 19. J Urol. 2017. PMID: 28433642
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
